The US Food and Drug Administration (FDA) holds a public hearing on psychedelic-assisted therapies, gathering testimony from medical professionals and other stakeholders. The session takes place in Silver Spring, Maryland and spans four hours.
At the hearing, doctors, veterans, pharmacists, and therapists call for clear guidance on safety and access, including expectations for provider training. Several speakers urge the regulator to establish standards that address how treatments are delivered and who is eligible to provide or receive care.
The outlets describe the hearing as part of a broader push for faster approvals linked to the Trump administration. While the coverage focuses on different aspects—such as safety standards, access, and operational requirements—both accounts highlight that speakers are trying to shape how the FDA approaches regulatory clarity for psychedelic-assisted therapies.
